dc.contributor.author
Rogasch, Julian M. M.
dc.contributor.author
Hundsdoerfer, Patrick
dc.contributor.author
Hofheinz, Frank
dc.contributor.author
Wedel, Florian
dc.contributor.author
Schatka, Imke
dc.contributor.author
Amthauer, Holger
dc.contributor.author
Furth, Christian
dc.date.accessioned
2019-04-15T14:15:30Z
dc.date.available
2019-04-15T14:15:30Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/24421
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-2193
dc.description.abstract
Background: Standardized treatment in pediatric patients with Hodgkin's lymphoma (HL) follows risk stratification by tumor stage, erythrocyte sedimentation rate and tumor bulk. We aimed to identify quantitative parameters from pretherapeutic FDG-PET to assist prediction of response to induction chemotherapy. Methods: Retrospective analysis in 50 children with HL (f:18; m:32; median age, 14.8 [4-18] a) consecutively treated according to EuroNet-PHL-C1 (n = 42) or -C2 treatment protocol (n = 8). Total metabolic tumor volume (MTV) in pretherapeutic FDG-PET was defined using a semi-automated, background-adapted threshold. Metabolic (SUVmax, SUVmean, SUVpeak, total lesion glycolysis [MTV*SUVmean]) and heterogeneity parameters (asphericity [ASP], entropy, contrast, local homogeneity, energy, and cumulative SUV-volume histograms) were derived. Early response assessment (ERA) was performed after 2 cycles of induction chemotherapy according to treatment protocol and verified by reference rating. Prediction of inadequate response (IR) in ERA was based on ROC analysis separated by stage I/II (1 and 26 patients) and stage III/IV disease (7 and 16 patients) or treatment group/level (TG/TL) 1 to 3. Results: IR was seen in 28/50 patients (TG/TL 1, 6/12 patients; TG/TL 2, 10/17; TG/TL 3, 12/21). Among all PET parameters, MTV best predicted IR; ASP was the best heterogeneity parameter. AUC of MTV was 0.84 (95%-confidence interval, 0.69-0.99) in stage I/II and 0.86 (0.7-1.0) in stage III/IV. In patients of TG/TL 1, AUC of MTV was 0.92 (0.74-1.0); in TG/TL 2 0.71 (0.44-0.99), and in TG/TL 3 0.85 (0.69-1.0). Patients with high vs. low MTV had IR in 86 vs. 0% in TG/TL 1, 80 vs. 29% in TG/TL 2, and 90 vs. 27% in TG/TL 3 (cut-off, > 80 ml, > 160 ml, > 410 ml). Conclusions: In this explorative study, high total MTV best predicted inadequate response to induction therapy in pediatric HL of all pretherapeutic FDG-PET parameters - in both low and high stages as well as the 3 different TG/TL.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Pediatric Hodgkin's lymphoma
en
dc.subject
Early response assessment
en
dc.subject
Metabolic tumor volume
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Pretherapeutic FDG-PET total metabolic tumor volume predicts response to induction therapy in pediatric Hodgkin's lymphoma
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
521
dcterms.bibliographicCitation.doi
10.1186/s12885-018-4432-4
dcterms.bibliographicCitation.journaltitle
BMC Cancer
dcterms.bibliographicCitation.number
1
dcterms.bibliographicCitation.originalpublishername
BMC
dcterms.bibliographicCitation.volume
18
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
29724189
dcterms.isPartOf.issn
1471-2407